Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial. Online Data Supplement
|
|
- Suzanna Little
- 5 years ago
- Views:
Transcription
1 Blood Eosinophils and Response to Maintenance COPD Treatment: Data from the FLAME Trial Nicolas Roche, Kenneth R. Chapman, Claus F. Vogelmeier, Felix JF Herth, Chau Thach, Robert Fogel, Petter Olsson, Francesco Patalano, Donald Banerji and Jadwiga A. Wedzicha Online Data Supplement
2 METHODS Following a 1-week screening period and 4-week run-in period (in which patients received tiotropium 18 μg once daily) patients discontinued tiotropium and were randomized 1:1 to indacaterol/glycopyrronium (IND/GLY) 110/50 μg once daily or salmeterol/fluticasone propionate combination (SFC) 50/500 μg twice daily for 52 weeks, followed by a 30-day follow-up (Figure E1). Patients were provided with a salbutamol inhaler for use as rescue medication during the study. The study was conducted according to the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all patients. Assessments and Variables Patients recorded their daily symptoms in an electronic diary. When exacerbation criteria were met, patients received an alert and were advised to contact the site. All exacerbation events were documented using the chronic obstructive pulmonary disease (COPD) exacerbation electronic case report form (ecrf), including those which required healthcare utilization, with exacerbation severity determined by the type of treatment provided. Health status was assessed using the St George s Respiratory Questionnaire (SGRQ-C) on Weeks 4, 12, 26, 38, and 52 (or at treatment discontinuation). Forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) were recorded at 45 and 15 min pre-dose, and 30 min and 1 hour post-dose on Day 1 and Weeks 4, 12, 26, 38, and 52 (or at treatment discontinuation) using centralized spirometry. Rescue medication use was captured using the ediary. E2
3 Safety was assessed through recording adverse events and serious adverse events, including regular monitoring of hematology, blood chemistry, and urine, and regular assessments of vital signs, physical condition, and body weight. A pneumonia diagnosis required radiographic imaging via chest x-ray or computed tomography scan. All deaths, serious cardio- and cerebrovascular events, and atrial fibrillation/flutter events that occurred during the study were assessed by an independent adjudication committee. Statistical Analyses Efficacy analyses were performed on the modified intention-to-treat set which included all patients who underwent randomization, received at least one dose of a drug during the treatment period, and did not have major violations of compliance with Good Clinical Practice guidelines before unblinding occurred. Exacerbation rate was analyzed using a negative binomial model, including terms for treatment, baseline smoking status, prior inhaled corticosteroid (ICS) use, airflow limitation, region, subgroup term and treatment by subgroup interaction as fixed effects, with baseline total symptom score and COPD exacerbation history as covariates. Time to first exacerbation was analyzed using a Cox regression model, utilizing the same terms as the negative binomial model. Change from baseline in SGRQ-C total score was analyzed using a mixed model for repeated measures, with terms of treatment, baseline measurements, smoking status at baseline, baseline ICS use, airflow limitation, region, visit (as a factor), subgroup term, treatment-by-visit interaction, baseline-by-visit interaction, treatment- E3
4 by-subgroup term interaction, visit-by-subgroup term interaction, treatment-by-visitby-subgroup term interaction and an unstructured variance covariance structure. The proportion of patients who achieved a 4 unit reduction in total SGRQ-C score (1) was analyzed using repeated measurements logistic regression model with the same terms as the analysis of SGRQ-C score. Change from baseline in trough FEV1 and FVC were analyzed using a similar model as described for SGRQ-C measures, using appropriate baseline values. Change from baseline in daily rescue medication use over the 52-week treatment period was analyzed using a mixed model, with terms of treatment, baseline mean daily use of rescue medication, smoking status at baseline, baseline ICS use, airflow limitation, region, subgroup term and a treatment by subgroup interaction as fixed effects, with center nested within region as a random effect. The full pre-specified statistical analysis plan can be found in the Supplementary Appendix of Wedzicha JA, et al. N Engl J Med 2016 (2). Table E1 lists the pre-specified and post-hoc analyses discussed in this manuscript. Safety endpoints were assessed using the safety set (all patients who received at least one dose of study drug), and patients were analyzed according to the treatment they received. Further information on safety assessment has been published previously (2). E4
5 RESULTS Patient Demographics Baseline blood eosinophil percentage was similar in the IND/GLY and SFC treatment arms, as were mean and median baseline absolute cell count (Figure E2 and Table E2). 60.9% of patients had blood eosinophils 2% at baseline (Table E3). Health Status IND/GLY significantly improved mean SGRQ-C score compared with SFC at Week 52 in the < 2% subgroup, and provided a slight numerical improvement versus SFC in the 2% subgroup (Table E4). IND/GLY also significantly improved the proportion of patients achieving a 4-unit change in SGRQ-C total score compared with SFC at Week 52 in the < 2% subgroup and provided a numerical improvement versus SFC in the 2% subgroup (Table E4). Similarly, IND/GLY significantly improved mean SGRQ-C score and the proportion of SGRQ-C responders compared with SFC at Week 52 in the < 150 and < 300 cells/μl subgroups. Numerical improvements with IND/GLY versus SFC were observed in the 150 subgroup for both endpoints. IND/GLY provided similar improvements to SFC in the 300 cells/µl subgroup (Table E4). Lung Function IND/GLY significantly improved trough FEV1 and FVC compared with SFC at Week 52 in both the < 2% and 2% subgroups. IND/GLY also significantly improved E5
6 trough FEV1 and FVC compared with SFC at Week 52 in the < 150 and 150 cells/μl, and < 300 and 300 cells/μl subgroups (Table E5). Rescue Medication Use IND/GLY significantly reduced rescue medication use over 52 weeks compared with SFC in both the < 2% and 2% subgroups. IND/GLY also significantly reduced rescue medication use compared with SFC over 52 weeks in the < 150 and 150 cells/μl, and < 300 cells/μl subgroups. IND/GLY numerically reduced rescue medication use versus SFC in the 300 cells/μl subgroup (Table E6). Safety The incidence of adverse events and serious adverse events was similar between both treatment arms and between the <2% and 2% subgroups (Table E7). The number of adjudicated major adverse cardiac events and/or cardiovascular deaths was low, and was similar between both treatment arms (Table E8). Change in Blood Eosinophils Between Run-in Visit and Baseline by ICS Use In the total population, there was a small increase in mean (0.3%; 21 cells/μl) and median (0.1%; 0 cells/μl) blood eosinophils between screening and baseline (Table E9). E6
7 SUPPLEMENTARY FIGURES Figure E1. Timing of blood eosinophil measurements during FLAME Definition of abbreviations: b.i.d. = twice daily; Blood eos = blood eosinophils; GLY = glycopyrronium; IND = indacaterol; OL = open label; q.d. = once daily; SFC = salmeterol/fluticasone propionate combination. From The New England Journal of Medicine, Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Indacaterol Glycopyrronium versus Salmeterol Fluticasone for COPD, 2016;9;374(23): Copyright E7
8 (notice year) Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society." E8
9 Figure E2. Box plot of baseline blood eosinophils by A) percentage (%) and B) absolute cell count (cells/µl) A B Box-whisker plot with minimum, median, 25th and 75th percentiles and maximum is shown. The values represent baseline blood eosinophils, measured at randomization. Subjects with 600 cell/µl blood eosinophils were excluded before the run-in period at the run-in visit (Visit 101). Baseline is defined as the pre-dose value at randomization (scheduled Day 1, 45 to 20 min pre-dose) or, if missing, as last value measured prior to first dose. The ranges in B exceed 600 cells/µl as a patient with <600 cells/µl blood eosinophils at the run-in visit could theoretically have blood eosinophils 600 cell/µl at baseline, either due to natural variability or exposure to allergens. Definition of abbreviations: GLY = glycopyrronium; IND = indacaterol; SFC = salmeterol/fluticasone propionate combination. E9
10 SUPPLEMENTARY TABLES Table E1. Pre-specified and post-hoc statistical analyses Demographics Efficacy Endpoint Baseline demographic and clinical characteristics Rate of exacerbation (mild, moderate, severe) Statistical analysis Pre-specified in analysis plan Post-hoc analysis Summaries by blood eosinophil <2% and 2% Subgroup analysis by blood eosinophil <2% and 2% <3% and 3% <5% and 5% <150 cells/µl, 150 to <300 cells/µl, and 300 cells/µl Relationship with blood eosinophils as a continuous variable Rate of moderate/severe exacerbation Subgroup analysis by blood eosinophil <2% and 2% <3% and 3% <5% and 5% <150 cells/µl, 150 to <300 cells/µl, and 300 cells/µl Time to first exacerbation (mild, moderate, severe) Subgroup analysis by blood eosinophil <2% and 2% <3% and 3% <5% and 5% <150 cells/µl, 150 to <300 cells/µl, and 300 cells/µl E10
11 Time to first moderate/severe exacerbation SGRQ-C Change from baseline Proportion with 4- unit improvement Trough FEV 1 FVC Daily mean number of puffs or rescue medication Subgroup analysis by blood eosinophil <2% and 2% <3% and 3% <5% and 5% <150 cells/µl, 150 to <300 cells/µl, and 300 cells/µl Subgroup analysis by blood eosinophil <2% and 2% <150 cells/µl and 150 cells/μl <300 cells/µl and 300 cells/µl Subgroup analysis by blood eosinophil <2% and 2% <150 cells/µl and 150 cells/μl <300 cells/µl and 300 cells/µl Subgroup analysis by blood eosinophil <2% and 2% <150 cells/µl and 150 cells/μl <300 cells/µl and 300 cells/µl Safety Adverse event incidences MACE and/or CV deaths Subgroup analysis by blood eosinophil <2% and 2% Blood eosinophils Change between baseline and Weeks 26 and 52 Change between run-in and baseline visits * *Summary statistics (mean, median, etc.) for the change from baseline were pre-specified in the statistical analysis plan. The analysis using the mixed model for repeated measures was post-hoc. Definition of abbreviations: CV = cardiovascular; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; MACE = Major Adverse Cardiovascular Event; SGRQ-C = St George s Respiratory Questionnaire C E11
12 Table E2. Mean and median blood eosinophils at baseline Blood Eosinophils at Baseline IND/GLY 110/50 μg q.d. (n = 1,678) SFC 50/500 μg b.i.d. (n = 1,680) Percentage (%) Mean Q Median Q Absolute cell count (cells/μl) Mean cells/μl Q Median Q Analysis of the safety set (all patients who received at least one dose of study drug). Definition of abbreviations: b.i.d. = twice daily; GLY = glycopyrronium; IND = indacaterol; Q = quartile; q.d. = once daily; SFC = salmeterol/fluticasone propionate combination. E12
13 Table E3. Proportion of patients in blood eosinophil subgroups at baseline Proportion of Patients in Blood Eosinophil Subgroups at Baseline, n (%) IND/GLY SFC Blood Eosinophils 110/50 μg q.d. 50/500 μg b.i.d. Total at Baseline (n = 1,680) (n = 1,682) (N = 3,362) < 2% 629 (37.4) 672 (40.0) 1301 (38.7) 2% 1043 (62.1) 1005 (59.8) 2048 (60.9) < 3% 1056 (62.9) 1053 (62.6) 2109 (62.7) 3% 616 (36.7) 624 (37.1) 1240 (36.9) < 5% 1466 (87.3) 1463 (87.0) 2929 (87.1) 5% 206 (12.3) 214 (12.7) 420 (12.5) < 150 cells/μl 634 (37.7) 664 (39.5) 1298 (38.6) 150 to < 300 cells/μl 663 (39.5) 640 (38.0) 1303 (38.8) 300 cells/μl 375 (22.3) 373 (22.2) 748 (22.2) Definition of abbreviations: b.i.d. = twice daily; GLY = glycopyrronium; IND = indacaterol; q.d. = once daily; SFC = salmeterol/fluticasone propionate combination. E13
14 Table E4. Change in mean SGRQ-C total score from baseline to Week 52 and the proportion of patients with a 4-unit improvement in SGRQ- C total score from baseline to Week 52 by blood eosinophil subgroup Change in Mean SGRQ-C Total Score from Baseline to Week 52 Proportion of Patients with 4-unit Improvement in SGRQ-C Total Score from Baseline to Week 52 Blood Eosinophil IND/GLY SFC LSM Treatment IND/GLY SFC Subgroup 110/50 μg q.d. 50/500 μg b.i.d. Difference P value 110/50 μg q.d. 50/500 μg b.i.d. OR P value < 2% 3.4 (n = 604) 1.0 (n = 635) 2.4 < % (n = 604) 41.4% (n = 635) % 2.9 (n = 993) 2.4 (n = 954) % (n = 993) 45.2% (n = 954) < 150 cells/μl 3.3 (n = 610) 1.2 (n = 629) % (n = 610) 41.7% (n = 629) cells/μl 2.9 (n = 987) 2.3 (n = 960) % (n = 987) 45.0% (n = 960) E14
15 < 300 cells/μl 3.1 (n = 1,251) 1.6 (n = 1,236) % (n = 1,251) 43.3% (n = 1,236) cells/μl 2.9 (n = 346) 2.6 (n = 353) % (n = 346) 45.3% (n = 353) Definition of abbreviations: b.i.d. = twice daily; GLY = glycopyrronium; IND = indacaterol; LSM = least squares mean; OR = odds ratio; q.d. = once daily; SFC = salmeterol/fluticasone propionate combination; SGRQ-C = St George s Respiratory Questionnaire C. E15
16 Table E5. Change in pre-dose trough FEV 1 and FVC from baseline to Week 52 by blood eosinophil subgroup Change in Pre-dose Trough FEV 1 from Baseline to Week 52 (ml) Change in Pre-dose Trough FVC from Baseline to Week 52 (ml) Blood LSM Eosinophil IND/GLY SFC LSM Treatment IND/GLY SFC Treatment Subgroup 110/50 μg q.d. 50/500 μg b.i.d. Difference P value 110/50 μg q.d. 50/500 μg b.i.d. Difference P value < 2% 4 (n = 601) 68 (n = 636) 72 < (n = 601) 156 (n = 636) 151 < % 21 (n = 991) 35 (n = 955) 56 < (n = 991) 127 (n = 955) 165 < < 150 cells/μl 4 (n = 607) 64 (n = 631) 68 < (n = 607) 154 (n = 631) 159 < cells/μl 21 (n = 985) 37 (n = 960) 59 < (n = 985) 128 (n = 960) 161 < E16
17 < 300 cells/μl 7 (n = 1,246) 60 (n = 1,237) 67 < (n = 1,246) 149 (n = 1,237) 163 < cells/μl 41 (n = 346) 8 (n = 354) (n = 346) 103 (n = 354) 152 < Definition of abbreviations: b.i.d. = twice daily; FEV1 = forced expiratory volume in 1 second; FVC = forced vital capacity; GLY = glycopyrronium; IND = indacaterol; LSM = least squares mean; q.d. = once daily; SFC = salmeterol/fluticasone propionate combination. E17
18 Table E6. Change in mean daily numbers of puffs of rescue medication from baseline to Week 52 by blood eosinophil subgroup Change in Mean Daily Numbers of Puffs of Rescue Medication from Baseline to Week 52 (Puffs/Day) LSM Blood Eosinophil IND/GLY SFC Treatment Subgroup 110/50 μg q.d. 50/500 μg b.i.d. Difference P value < 2% (n = 608) (n = 648) % 0.99 (n = 996) 0.78 (n = 972) < 150 cells/μl 1.04 (n = 612) 0.70 (n = 643) cells/μl 0.98 (n = 992) 0.80 (n = 977) < 300 cells/μl 0.99 (n = 1,254) 0.73 (n = 1,257) 0.26 < cells/μl 1.05 (n = 350) 0.85 (n = 363) Definition of abbreviations: b.i.d. = twice daily; GLY = glycopyrronium; IND = indacaterol; LSM = least squares mean; q.d. = once daily; SFC = salmeterol/fluticasone propionate combination. E18
19 TABLE E7. Adverse and serious adverse events by <2% and 2% blood eosinophils <2% Blood Eosinophils at Baseline 2% Blood Eosinophils at Baseline IND/GLY SFC IND/GLY SFC 110/50 μg q.d. 50/500 μg b.i.d. 110/50 μg q.d. 50/500 μg b.i.d. Variable, n (%) (n = 629) (n = 672) (n = 1,044) (n = 1,004) Patients with at least one AE 535 (85.1) 593 (88.2) 919 (88.0) 902 (89.8) Adverse events in 3% in any treatment group Chronic obstructive pulmonary disease 478 (76.0) 546 (81.3) 817 (78.3) 825 (82.2) Nasopharyngitis 78 (12.4) 64 (9.5) 119 (11.4) 131 (13.0) Viral upper respiratory tract infection 49 (7.8) 51 (7.6) 83 (8.0) 87 (8.7) Upper respiratory tract infection bacterial 46 (7.3) 67 (10.0) 79 (7.6) 101 (10.1) Lower respiratory tract infection 29 (4.6) 44 (6.5) 53 (5.1) 54 (5.4) Pneumonia 26 (4.1) 37 (5.5) 27 (2.6) 43 (4.3) Upper respiratory tract infection 22 (3.5) 33 (4.9) 59 (5.7) 50 (5.0) E19
20 Hypertension 19 (3.0) 15 (2.2) 27 (2.6) 27 (2.7) Cough 17 (2.7) 27 (4.0) 33 (3.2) 24 (2.4) Influenza 15 (2.4) 23 (3.4) 20 (1.9) 33 (3.3) Oral candidiasis 10 (1.6) 30 (4.5) 10 (1.0) 41 (4.1) Dyspnea 9 (1.4) 21 (3.1) 39 (3.7) 30 (3.0) Bronchitis 9 (1.4) 13 (1.9) 20 (1.9) 31 (3.1) Serious AEs or AE discontinuations Death 6 (1.0) 14 (2.1) 17 (1.6) 9 (0.9) SAE(s) 113 (18.0) 136 (20.2) 194 (18.6) 196 (19.5) Discontinuation due to AE(s) 36 (5.7) 65 (9.7) 89 (8.5) 76 (7.6) Discontinuation due to SAE(s) 24 (3.8) 40 (6.0) 60 (5.7) 45 (4.5) Discontinuation due to non-sae(s) 15 (2.4) 33 (4.9) 34 (3.3) 36 (3.6) AEs requiring dose adjustment AEs requiring dose interruption 19 (3.0) 30 (4.5) 29 (2.8) 35 (3.5) AEs requiring additional therapy 397 (63.1) 451 (67.1) 681 (65.2) 705 (70.2) E20
21 The data are based on two different sources, adverse event ecrf and COPD exacerbation episode ecrf. A patient with multiple AEs is counted only once in the "at least one AE" row. A patient with multiple AEs with the same preferred term is counted only once for that preferred term. All adverse events starting on or after the time of first administration of double-blind drug but not later than 7 days (30 days in case of an SAE) after the last administration are included. Definition of abbreviations: AE = adverse event; b.i.d. = twice daily; COPD = chronic obstructive pulmonary disease; ecrf = COPD exacerbation electronic case report form; GLY = glycopyrronium; IND = indacaterol; q.d. = once daily; SAE = serious adverse event; SFC = salmeterol/fluticasone propionate combination. E21
22 Table E8. Number of adjudicated MACE and/or CV deaths <2% Blood Eosinophils at Baseline 2% Blood Eosinophils at Baseline MACE and/or IND/GLY SFC IND/GLY SFC Cardiovascular Death, 110/50 μg q.d. 50/500 μg b.i.d. 110/50 μg q.d. 50/500 μg b.i.d. n (%) (n = 629) (n = 672) (n = 1,044) (n = 1,004) MACE and/or cardiovascular death 9 (1.43) 8 (1.19) 22 (2.11) 22 (2.19) MACE 8 (1.27) 2 (0.30) 16 (1.53) 19 (1.89) Non-fatal myocardial infarction Non-fatal unstable angina 3 (0.48) 1 (0.15) 8 (0.77) 4 (0.40) Non-fatal stroke 2 (0.32) 1 (0.15) 4 (0.38) 7 (0.70) Heart failure requiring hospitalization 1 (0.16) 0 3 (0.29) 4 (0.40) Coronary revascularization 3 (0.48) 1 (0.15) 6 (0.57) 7 (0.70) (CABG or PCI) Cardiovascular death 1 (0.16) 6 (0.89) 7 (0.67) 4 (0.40) Classification was determined by an independent adjudication committee. All deaths were adjudicated. All MACE events and deaths on or after the time of first administration of double-blind drug but not later than 30 days after the last administration are included. Definition of abbreviations: b.i.d. = twice daily; CABG = coronary artery bypass graft; CV = cardiovascular; GLY = glycopyrronium; IND = indacaterol; MACE = Major Adverse Cardiovascular E22
23 Event; PCI = percutaneous coronary intervention; q.d. = once daily; SFC = salmeterol/fluticasone propionate combination. E23
24 Table E9. Change in blood eosinophils between run-in visit and baseline by ICS use ICS Use (n = 1,863) No ICS Use (n = 1,437) Total (n = 3,300) Run-in Visit Baseline Change Run-in Visit Baseline Change Run-in Visit Baseline Change Mean eosinophils, % (SD) 2.6 (1.64) 2.9 (2.12) 0.3 (1.77) 2.6 (1.70) 2.8 (2.02) 0.2 (1.63) 2.6 (1.66) 2.9 (2.08) 0.3 (1.71) Median ICS Use (n = 1,862) No ICS Use (n = 1,437) Total (n = 3,299) Run-in Visit Baseline Change Run-in Visit Baseline Change Run-in Visit Baseline Change Mean eosinophils, cells/μl (SD) 199 (122) 223 (176) 24 (148) 195 (124) 213 (159) 18 (130) 197 (123) 219 (169) 21 (140) Median Definition of abbreviations: b.i.d. = twice daily; GLY = glycopyrronium; ICS = inhaled corticosteroid; IND = indacaterol; q.d. = once daily; SD = standard deviation; SFC = salmeterol/fluticasone propionate combination. E24
25 REFERENCES 1. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005;2: Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier C. Indacaterol-glycopyrronium versus salmeterolfluticasone for COPD. N Engl J Med 2016;374: E25
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIndication: Treatment: Objectives: Primary Outcome/Efficacy Variable: Secondary Outcome/Efficacy Variable(s): Statistical Methods:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTractament farmacològic de l MPOC LAMA-LABA
Tractament farmacològic de l MPOC LAMA-LABA Pilar Ausín SABA-SAMA vs LABA-LAMA EPOC moderado 65 años Exfumador (50 PA) FEV 1 : 58% Camina: 400 m BMI: 23 Disnea grado 1 Estadio II de GOLD Función
More informationUMEC/VI vs. UMEC in subjects who responded to UMEC UMEC/VI vs. VI in subjects who responded to VI
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Co-Primary Outcomes/Efficacy Variables:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More informationรศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น
รศ. นพ. ว ชรา บ ญสว สด M.D., Ph.D. ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล ยขอนแก น COPD Guideline Changing concept in COPD management Evidences that we can offer COPD patients better life COPD Guidelines
More informationStudy No.: SFCA3007 Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS
Study No.: A3007 Title: A Randomized, Double-Blind, -Controlled, Parallel-Group Trial Evaluating the Safety and Efficacy of the DISKUS Formulations of Salmeterol (SAL) 50mcg BID and Fluticasone Propionate
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS A two-stage randomized, open-label, parallel group, phase III, multicenter, 7-month study to assess the efficacy and safety of SYMBICORT
Drug product: Drug substance(s): Edition No.: Study code: SYMBICORT pmdi 160/4.5 g Budesonide/formoterol D5896C00005 Date: 8 May 2006 SYNOPSIS A two-stage randomized, open-label, parallel group, phase
More informationINSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD
ORIGINAL ARTICLE COPD INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD Andrea Rossi 1, Thys van der Molen 2, Ricardo del Olmo 3, Alberto Papi 4, Luis Wehbe
More informationSYNOPSIS. Study center(s) This study was conducted in the United States (128 centers).
Drug product: Drug substance(s): Document No.: Edition No.: Study code: Date: SYMBICORT pmdi 160/4.5 µg Budesonide/formoterol SD-039-0725 17 February 2005 SYNOPSIS A Twelve-Week, Randomized, Double-blind,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor Novartis Pharmaceuticals
Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol maleate-glycopyrronium bromide Trial Indication(s) Chronic obstructive pulmonary disease Protocol Number CQVA149A2339 Protocol Title A placebo
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
ERJ Express. Published on May 30, 2013 as doi: 10.1183/09031936.00200212 1 Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study Eric D Bateman*, Gary T Ferguson #, Neil
More informationAclidinium bromide/formoterol Endpoint category. RR Endpoint. [95% CI 2 ] Study. with event
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationOptimum treatment for chronic obstructive pulmonary disease exacerbation prevention
Commentary Page 1 of 5 Optimum treatment for chronic obstructive pulmonary disease exacerbation prevention Pradeep Karur, Dave Singh Centre for Respiratory Medicine and Allergy, Medicines Evaluation Unit,
More informationThree better than 1 or 2?
Three better than 1 or 2? DISCLOSURE Pam McLean-Veysey, Team Leader Drug Evaluation Unit DEU funded by the Drug Evaluation Alliance of NS. (DEANS). DEU prepares Drug Evaluation Reports for the Atlantic
More informationTurning Science into Real Life Roflumilast in Clinical Practice. Roland Buhl Pulmonary Department Mainz University Hospital
Turning Science into Real Life Roflumilast in Clinical Practice Roland Buhl Pulmonary Department Mainz University Hospital Therapy at each stage of COPD I: Mild II: Moderate III: Severe IV: Very severe
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationIndacaterol Glycopyrronium versus Salmeterol Fluticasone for COPD
The new england journal of medicine Original Article Indacaterol Glycopyrronium versus Salmeterol Fluticasone for COPD Jadwiga A. Wedzicha, M.D., Donald Banerji, M.D., Kenneth R. Chapman, M.D., Jørgen
More informationPulmonary Year in Review
Pulmonary Year in Review Rachel Givelber, MD University of Pittsburgh SOM Pulmonary, Allergy, Critical Care and Sleep Medicine Rachel Givelber, MD Assistant Professor of Medicine PACCM, UPSOM Disclosures
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationSYNOPSIS. First subject enrolled 15 August 2003 Therapeutic confirmatory (III) Last subject completed 03 February 2005
Drug product: SYMBICORT pmdi 160/4.5 μg Drug substance(s): Budesonide/formoterol Study code: SD-039-0728 Edition No.: FINAL Date: 27 February 2006 SYNOPSIS A 52-week, randomized, double-blind, single-dummy,
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationEvidence Summary to support COPD formulary decision making and guideline development
Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final pages of this document. Anoro, and Ellipta
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationPotential risks of ICS use
Potential risks of ICS use Randomised controlled trial Observational study Systematic review Pneumonia Tuberculosis Bone fracture Skin thinning/easy bruising Cataract Diabetes No effect on fracture risk
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD)
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) Zahava Picado, PharmD PGY1 Pharmacy Practice Resident Central Texas Veterans Healthcare System Temple, TX October
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationResearch in Real Life
Research in Real Life Study 1: Exploratory study - identifying the benefits of pmdi versus Diskus for delivering fluticasone/salmeterol combination therapy in patients with chronic obstructive pulmonary
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationResearch Review. Salmeterol/fluticasone propionate (Seretide ) in COPD. Extended listing for salmeterol/fluticasone propionate in COPD
Research Review Salmeterol/fluticasone propionate (Seretide ) in COPD Extended listing for salmeterol/fluticasone propionate in COPD In New Zealand, salmeterol/fluticasone propionate (SFC) (Seretide )
More informationumeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline
umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline 04 July 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationSYNOPSIS THIS IS A PRINTED COPY OF AN ELECTRONIC DOCUMENT. PLEASE CHECK ITS VALIDITY BEFORE USE.
Drug product: Drug substance(s): Document No.: Edition No.: 1 Study code: Accolate Zafirlukast (ZD9188) 9188IL/0138 Date: 02 May 2007 SYNOPSIS A Multicenter, Randomized, Double-blind, -controlled, Parallel
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study
ORIGINAL ARTICLE COPD Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study Eric D. Bateman 1, Gary T. Ferguson 2, Neil Barnes 3, Nicola Gallagher 4, Yulia Green 4, Michelle
More informationEvidence Summary to support COPD formulary decision making and guideline development
Evidence Summary to support COPD formulary decision making and guideline development Prescribing and adverse event reporting information can be found on the final page of this document. Trelegy and Ellipta
More informationChronic obstructive pulmonary disease (COPD) is characterized
DANIEL E. HILLEMAN, PharmD ABSTRACT OBJECTIVE: To review the role of long-acting bronchodilators in the treatment of chronic obstructive pulmonary disease (COPD), including the importance of treatment
More informationCOPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK
COPD EXACERBATIONS AND HOSPITAL ADMISSIONS HOW CAN WE PREVENT THEM? Wisia Wedzicha National Heart and Lung Institute, Imperial College London, UK Presenter Disclosures Wisia Wedzicha All disclosures prior
More informationSYNOPSIS. Drug substance(s) Budesonide/formoterol Document No. Edition No. Study code SD Date 16 December 2004
Drug product SYMBICORT pmdi 160/4.5 µg SYNOPSIS Drug substance(s) Budesonide/formoterol Document No. Edition No. Date 16 December 2004 A Twelve-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 micro g twice daily and budesonide 800 micro g twice daily in the treatment of adults and adolescents with asthma Lundback
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationOutcomes: Initially, our primary definitions of pneumonia was severe pneumonia, where the subject was hospitalized
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Date 15 June 2004
Drug product Drug substance(s) Document No. Edition No. Study code SYMBICORT pmdi 160/4.5 mg per actuation Budesonide/formoterol SD-039-0719 Date 15 June 2004 SYNOPSIS A Six-Month, Randomized, Open-Label
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationD DAVID PUBLISHING. 1. Introduction
Journal of Health Science 2 (2014) 591-598 doi: 10.17265/2328-7136/2014.12.004 D DAVID PUBLISHING Comparative Efficacy and Safety of Two Formulations of Ipratropium Bromide (IB) HFA pmdi in Patients with
More informationInternational co-ordinating investigator Dr Dencho Osmanliev, St Sofia, Pulmonary Dept, 19 D Nestorov Str, Sofia, 1431, Bulgaria.
Drug product: SYNOPSIS Drug substance(s): Budesonide/formoterol Document No.: SD-039-CR-0681 Referring to part Edition No.: 1 of the dossier Study code: SD-039-0681 Date: 24 Oktober, 2003 (For national
More informationConfronting the Challenges of COPD. What is New in The Approaches to Diagnosis, Treatment, and Patient Outcomes
Confronting the Challenges of COPD What is New in The Approaches to Diagnosis, Treatment, and Patient Outcomes COPD Definition GOLD: Global Initiative for Chronic Obstructive Lung Disease Common, preventable,
More informationCOPD Therapeutic Update
COPD Therapeutic Update The first ever NT patient.. Hubertus PA Jersmann MBBS, MD, PhD, FRACP, FThorSoc, AMA(M) Professor, School of Medicine, University of Adelaide Respiratory and Sleep Physician, Royal
More informationClinical Trial Synopsis TL-OPI-518, NCT#
Clinical Trial Synopsis, NCT# 00225264 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl vs Glimepiride
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationRescue medication use as a patientreported outcome in COPD: a systematic review and regression analysis
Punekar et al. Respiratory Research (2017) 18:86 DOI 10.1186/s12931-017-0566-1 RESEARCH Rescue medication use as a patientreported outcome in COPD: a systematic review and regression analysis Yogesh Suresh
More informationA randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD
ORIGINAL ARTICLE COPD A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD Tara Rheault 1, Sanjeev Khindri 2, Mitra Vahdati-Bolouri 2, Alison Church 1 and William
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationManagement of COPD Updates and Evidence
Management of COPD Updates and Evidence Providence Alaska Medical Center PGY1 Pharmacy Practice Residents Ann-Chee Cheng, PharmD Kaite Kammers, PharmD http://www.fpnotebook.com/_media/lungxsgraybb962.gif
More informationSystematic review of inhaled corticosteroid withdrawal effects in chronic obstructive pulmonary disease, and comparison with two real-life studies
Review Article Systematic review of inhaled corticosteroid withdrawal effects in chronic obstructive pulmonary disease, and comparison with two real-life studies Wenjing Ye, Xuejun Guo, Tianyun Yang, Fengfeng
More informationAPPENDIX EXHIBITS. Appendix Exhibit A2: Patient Comorbidity Codes Used To Risk- Standardize Hospital Mortality and Readmission Rates page 10
Ross JS, Bernheim SM, Lin Z, Drye EE, Chen J, Normand ST, et al. Based on key measures, care quality for Medicare enrollees at safety-net and non-safety-net hospitals was almost equal. Health Aff (Millwood).
More informationNEW OPTIONS FOR OPTIMAL BRONCHODILATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
NEW OPTIONS FOR OPTIMAL BRONCHODILATION IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE *Caroline Charles Scilink Medical Writing *Correspondence to scilink.mw@gmail.com Disclosure: Medical writing assistance
More informationLead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984]
Lead team presentation: Roflumilast for treating chronic obstructive pulmonary disease [ID984] 1 st Appraisal Committee meeting Background & Clinical Effectiveness John McMurray 11 th January 2016 For
More informationAclidinium bromide/ formoterol Benefit assessment according to 35a Social Code Book V 1
IQWiG Reports Commission No. A15-06 Aclidinium bromide/ formoterol Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Aclidiniumbromid/Formoterol
More informationSponsor Novartis. Generic Drug Name Fluvastatin. Therapeutic Area of Trial Dyslipidemia
Page 1 Sponsor Novartis Generic Drug Name Fluvastatin Therapeutic Area of Trial Dyslipidemia Approved Indication Therapeutic area and approved indications in Germany: Hypercholesterolemia (HC), combined
More informationFEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2010 FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery Nicholas L Mills, David A McAllister, Sarah Wild, John D MacLay,
More informationGlycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials
pul- Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials The clinical development of the long-acting muscarinic antagonist bronchodilator glycopyrronium
More informationPharmacological Management of Obstructive Airways in Humans. Introduction to Scientific Research. Submitted: 12/4/08
Pharmacological Management of Obstructive Airways in Humans Introduction to Scientific Research Submitted: 12/4/08 Introduction: Obstructive airways can be characterized as inflammation or structural changes
More informationWhat s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university
What s new in COPD? Apichart Khanichap MD. Department of Medicine, Faculty of Medicine, Thammasat university Management stable COPD Relieve symptoms Improve exercise tolerance Improve health status Prevent
More informationModel based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking
Model based longitudinal metaanalysis of FEV1 in COPD trials A tool for efficacy benchmarking Julia Korell (1), Steven W. Martin (2), Mats O. Karlsson (1), Jakob Ribbing (1,3) (1) Uppsala University, Sweden
More informationClinical Trial Synopsis TL-OPI-516, NCT#
Clinical Trial Synopsis, NCT#00225277 Title of Study: A Double-Blind, Randomized, Comparator-Controlled Study in Subjects With Type 2 Diabetes Mellitus Comparing the Effects of Pioglitazone HCl Versus
More informationMepolizumab (asthma)
IQWiG Reports Commission No. A16-33 Mepolizumab (asthma) Addendum to Commission A16-03 1 Addendum Commission:A16-33 Version: 1.0 Status: 29 June 2016 1 Translation of addendum A16-33 Mepolizumab (Asthma)
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationStep-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide.
Step-down approach in chronic stable asthma: A comparison of reducing dose Inhaled Formoterol/ Budesonide with maintaining Inhaled Budesonide. By: DR MOHD SHAMSUL AMRI Supervisor: Associate Professor Dr
More informationJournal of the COPD Foundation. Journal Club. Chronic Obstructive Pulmonary Diseases:
85 Journal Club Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation Journal Club Ron Balkissoon, MD, MSc, DIH, FRCPC 1 Abbreviations: inhaled corticosteroid, ICS; long acting β 2 -agonist,
More informationWho can get most benefit
Who can get most benefit from tiotropium in asthma? Y-M. Oh Asan Medical Center Univ. of Ulsan College of Medicine Seoul, Korea Tiotripium for Asthma 1 New in GINA 2015 Add-on tiotropium by soft-mist inhaler
More informationCDEC FINAL RECOMMENDATION
CDEC FINAL RECOMMENDATION (FLUTICASONE FUROATE/VILANTEROL) (Breo Ellipta GlaxoSmithKline) Indication: Chronic Obstructive Pulmonary Disease Recommendation: The Canadian Drug Expert Committee (CDEC) recommends
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationSupplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Glycopyrronium bromide (Seebri Breezhaler ) 44 micrograms inhalation powder as hard capsules
AWMSG SECRETARIAT ASSESSMENT REPORT Glycopyrronium bromide (Seebri Breezhaler ) 44 micrograms inhalation powder as hard capsules Reference number: 1455 FULL SUBMISSION This report has been prepared by
More informationmonotherapy were permitted throughout all trials.
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Month/Year of Review: February 2012 End date of literature
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Lembo AJ, Lacy BE, Zuckerman MJ, et al. Eluxadoline for irritable
More informationUPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
UPDATE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE Radhika Shah, MD Erlanger Health System University of Tennessee College of Medicine Chattanooga Respiratory, Critical Care, and Sleep medicine No disclosures
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder. Reference number: 938 FULL SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder Reference number: 938 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics
More informationNuovi farmaci in sviluppo per la BPCO
PNEUMOLOGIA 2018 MILANO, 14 16 GIUGNO 2018 CENTRO CONGRESSI PALAZZO DELLE STELLINE Nuovi farmaci in sviluppo per la BPCO Leonardo M. Fabbri, MD, FERS Professor of Respiratory and Internal Medicine, University
More information